Amidst a resurgence with the Pittsburgh Steelers, Russell Wilson has no intentions of hanging up his spikes in the immediate future. ESPN's Hannah Storm conducted an interview with Wilson that ...

Pittsburgh Steelers quarterback Russell Wilson is 35 years old, but he isn't planning on retiring anytime soon. "I definitely want to play another five to seven years," he told ESPN's Hannah Storm ...

As long-suffering Jets fans process another losing season, they’ve noticed how little improvement Rodgers has offered them over former quarterback Zach Wilson. His stats don’t pop out in most ...

Russell Wilson's wife Ciara is celebrating 20 years in the music business with a special cover spread in Hia Magazine. The wife of the Pittsburgh Steelers quarterback took to Instagram to share ...

The New York Jets season has been the stuff of nightmares through the first 10 games, posting a 3-7 record and looking anything but a playoff team. With so much talent on the roster, for whatever ...

However, even though the Steelers are currently outside the top-10 in those categories, they're climbing quickly. Since Russell Wilson was inserted into the starting lineup, the Steelers are 3-0 and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Brooklyn Nets forward Jalen Wilson was expected to see an increased role coming into the 2024-25 NBA season. The Nets are now 5-6, sitting at the sixth seed in the Eastern Conference, with that ...

Nifty50 PR 1x Inverse share price was up by 0.12% from the previous closing price of 211.10. What has been 52-week high of Nifty50 PR 1x Inverse stocks? The highest price of Nifty50 PR 1x Inverse ...

Last year, AstraZeneca reported that a new drug to treat Wilson disease developed by its Alexion rare diseases unit had hit the mark in a phase 3 trial, setting it on course for regulatory filings.